• Quest Launches First US HBV Test to Assess Patients’ Response to Therapy
  • Vemlidy, for Chronic Hepatitis B Infection, Approved in Europe
  • AbbVie’s One-Pill Combo Therapy Shows Promise for Hepatitis C in Japanese Trial
  • Blacks, Hispanics with Hepatitis C More Likely to Fail Treatment with Direct-Acting Antiviral Agents
  • ContraVir Awarded $224K Research Grant to Advance Potential Hepatitis B Treatment
  • Gilead Sciences Awards Grant to Promote Best Practices for HCV, HBV and HIV Screening
  • Combo of RNA Interference Therapies and Antiviral Agents Treat Hepatitis B in Early Study
  • Hepatitis C Therapy Sovaldi Can Adversely Interact with HIV Therapy Viread, Study Says
  • Health Professionals in Ethiopia Show Solid Knowledge of Hepatitis B in Hospital Survey
  • Gilead Submits New Drug Application for Once-daily Single Tablet Regimen for HCV
  • Models Seen to Predict Transmission Risk of HCV and HIV Infection in Drug Users
  • European Medical Officials Join Chorus of Warnings About Risk of Hep B Reactivation with Direct-Acting Antiviral Drugs Used for Hep C